Nutritional impact of active hexose-correlated compound for patients with resectable or borderline-resectable pancreatic cancer treated with neoadjuvant therapy
Nutritional impact of active hexose-correlated compound for patients with resectable or borderline-resectable pancreatic cancer treated with neoadjuvant therapy
复制标题
DOI：
10.1007/s00595-021-02308-3
复制
发表时间：
2021-06-04
期刊：
影响因子：
2.5
通讯作者：
Sekimoto, Mitsugu
中科院分区：
文献类型：
--
作者：
Hashimoto, Daisuke;Satoi, Sohei;Sekimoto, Mitsugu
活性己糖相关化合物（AHCC）是从培养的香菇菌丝体中提取的标准化提取物，在癌症治疗中用作有效的生物反应调节剂。我们评估了新辅助治疗期间给予AHCC对胰腺导管腺癌（PDAC）患者的营养作用。30例可切除或边缘可切除的PDAC患者接受吉西他滨加S-1的新辅助治疗。我们回顾性比较了15例接受AHCC联合新辅助治疗的患者与15例未接受AHCC联合新辅助治疗的患者的结局。嗜中性粒细胞与淋巴细胞比率（NLR）和预后营养指数（PNI）的中位数变化在AHCC组中明显更好。新辅助治疗的相对剂量强度在AHCC组中也显著较高。因此，AHCC可以改善胰腺导管腺癌患者新辅助治疗期间的营养状况。为了验证这些结果并检查AHCC的长期影响，正在进行PDAC的前瞻性II期研究。
Active hexose-correlated compound (AHCC) is a standardized extract from cultured Lentinula edodes mycelia, used as a potent biological response modifier in cancer treatment. We evaluated the nutritional effect of AHCC, given during neoadjuvant therapy, to patients with pancreatic ductal adenocarcinoma (PDAC). Thirty patients with resectable or borderline-resectable PDAC received neoadjuvant therapy with gemcitabine plus S-1. We compared, retrospectively, the outcomes of 15 patients who received AHCC combined with neoadjuvant therapy with those of 15 patients who did not receive AHCC combined with neoadjuvant therapy. The median changes of the neutrophil-to-lymphocyte ratio (NLR) and prognostic nutrition index (PNI) were significantly better in the AHCC group. The relative dose intensity of neoadjuvant therapy was also significantly higher in the AHCC group. Thus, AHCC may improve the nutritional status during neoadjuvant therapy of patients with pancreatic ductal adenocarcinoma. To validate these results and examine the long-term impact of AHCC, a prospective phase II study for PDAC is ongoing.